Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin injection MET-233i showed promising weight-loss over about eight months.